Kyle R. Berg

Kyle R. Berg

Auto-generated profile, based on publicly available information

Kyle R. Berg

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA; Department of Chemistry, University of California, San Diego, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Molecular Cell
Verified
Journal Article
Closed access
RLRebecca K. Lau
Rebecca K. Lau
QYQiaozhen Ye
Qiaozhen Ye
EBErica A. Birkholz
Erica A. Birkholz
KBKyle R. Berg
Kyle R. Berg
LPLucas Patel
Lucas Patel
KCKevin D. Corbett
Kevin D. Corbett

14 January 2020 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
JCJessica L. Cifelli
Jessica L. Cifelli
KBKyle R. Berg
Kyle R. Berg
JYJerry Yang
Jerry Yang
Synaptic dysfunction has been implicated as an early cause of cognitive decline in neurodegenerative diseases (NDDs) such as Alzheimer’s disease (AD). Methods to slow down or reverse the loss of functional synapses, therefore, represent a promising avenue to explore for treating NDDs. We have previously reported the development of a class of benzothiazole amphiphiles (BAMs) that exhibited the capability to improve memory and learning both in wild‐type mice and in an AD rodent model, putatively through promoting RasGRF1‐associated formation of dendritic spines in hippocampal neurons. While these results represent a good first step in exploring a new approach to treating NDDs, the capability of these compounds to increase spine density has not been previously examined in a human neuronal model. Here, we found that neurons derived from differentiated human induced pluripotent stem cells exhibited both an increase in RasGRF1 expression and a phenotypic increase in the density of postsynaptic density protein 95‐positive puncta (which we use to provide an estimate of dendritic spine density) in BAM‐treated vs. control neurons. These results demonstrate that the previously observed spinogenic effects of BAMs in rodent neurons can be recapitulated in a human neuronal model, which further supports the potential utility of BAM agents for treating human diseases associated with spine deficits such as AD or other NDDs.

7 July 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
RLRebecca K. Lau
Rebecca K. Lau
QYQiaozhen Ye
Qiaozhen Ye
LPLucas Patel
Lucas Patel
KBKyle R. Berg
Kyle R. Berg
IMIan T. Mathews
Ian T. Mathews
KCKevin D. Corbett
Kevin D. Corbett
Bacteria possess an array of defenses against foreign invaders, including diverse nucleases that target and destroy the genome of an invading bacteriophage or foreign DNA element. A recently-described bacteriophage immunity pathway employs a cGAS/DncV-like nucleotidyltransferase to produce a cyclic tri-AMP second messenger, which activates the DNA endonuclease effector NucC. Here, we show that NucC is related to restriction enzymes but uniquely assembles into a homotrimer in solution. cAAA binding in a conserved allosteric pocket promotes assembly of two NucC trimers into a homohexamer competent for double-strand DNA cleavage. We propose that NucC mediates bacteriophage immunity either through global activation, causing altruistic cell death and abortive infection, or through local activation and targeted phage genome destruction. Finally, we identify NucC homologs in type III CRISPR-Cas systems, where they likely function as accessory nucleases activated by cyclic oligoadenylate second messengers synthesized by these systems’ effector complexes.